Lenvatinib: 12 milligram (mg) based on the participant's body weight greater than or equal to (≥) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD)
Study summary
This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib. The study will include two groups: patients who started lenvatinib as first-line (1L) treatment and patients who started lenvatinib as second-line (2L) treatment after prior 1L immunotherapy was stopped because the cancer progressed or because of toxicity. All study information will be collected retrospectively from existing patient records. Patients will be followed from the start of lenvatinib until death or their last documented follow-up before data extraction.
The primary objectives of this study are:
* To retrospectively evaluate the effectiveness of 1L lenvatinib in a real-world setting as measured by overall survival (OS)
* To retrospectively evaluate the effectiveness of 2L lenvatinib as measured by OS after progression on or discontinuation of prior 1L immunotherapy
* 1L immunotherapies to be considered include atezolizumab plus bevacizumab (Atezo/Bev) or durvalumab plus tremelimumab (Durva/Treme) combination therapies, based on preferred regimens listed by National Comprehensive Cancer Network (NCCN) 2025 guidelines
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosed with uHCC, as confirmed by radiology, histology, or cytology
* 18 years of age at the time of Lenvatinib initiation for uHCC
* Initiated, within standard clinical practice, 1L Lenvatinib (Cohort A) or initiated 2L Lenvatinib after progression on or discontinuation (due to toxicity) of prior immunotherapy (Cohort B) between 01 Sep 2020 and 30 Sep 2023
* BCLC Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy at initial diagnosis of metastatic uHCC
* At least one measurable target lesion at Lenvatinib initiation
* ECOG performance status 0 or 1 at Lenvatinib initiation
* If deceased, have a reported date of death.
Cohort A
* Child-Pugh A (score 5 or 6) classification of uHCC at Lenvatinib initiation
* Initiated Lenvatinib with US FDA approved starting dose (12 mg once daily for patients weighing ≥60 kg, or 8 mg once daily for patients weighing \<60 kg
Cohort B
* Patients may have either Child-Pugh A (score 5 or 6) or Child-Pugh B (score 7) classification of uHCC at Lenvatinib initiation
Exclusion Criteria:
* Vp4 at Lenvatinib initiation
* Esophageal or gastric variceal bleeding within 6 months before the index date
* Had a prior history of other malignancy that required active treatment; exceptions include non-melanoma skin cancer or in situ cervical cancer that has potentially curative therapy underwent
* History of liver transplant
Cohort A
* Received other 1L systemic therapy or LRT concurrently with Lenvatinib
Cohort B
* Received other immunotherapy not inclusive of atezolizumab plus bevacizumab or durvalumab plus tremelimumab combination therapies
* Received other 2L systemic therapy or LRT concurrently with Lenvatinib
Primary outcome measure(s)
Cohort A Overall Survival (OS) — From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years) Retrospectively evaluate the effectiveness of 1L Lenvatinib in a real-world setting
Cohort B OS — From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years) Retrospectively evaluate the effectiveness of 2L Lenvatinib
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
